iFAST Diagnostics UK diagnostics company iFAST Diagnostics has announced the successful close of its $6.5 million (£5 million) seed round. iFAST has developed a technology that tests bacteria to determine the most effective antibiotics in under three hours.
The company says this is a significant advancement compared to the current 48-72 hours required. Using a microchip to analyse thousands of bacteria electrically, the system ensures that patients get the right treatment faster, potentially saving lives, especially in critical cases like sepsis and drug-resistant infections. The oversubscribed round was led by KHP Ventures , the first NHS-anchored venture fund, with existing investors Qantx, UKI2S (Managed by Future Planet Capital), Kadmos, and angels reaffirming their commitment.
New investors EInk, RAW Ventures, and OKG Capital have also joined. Toby King, CEO of iFAST said: “We are incredibly excited to receive the investment we need to bring our technology to market just a couple of years after founding the company. The thought of saving patients’ lives through them having the correct antibiotic at the right time is hugely motivating for the whole team.
I’d like to thank all our existing investors for continuing to support us, and KHP in particular for leading the round, as well as EInk, RAW, and OKG for having the conviction to come on board at this pivotal time for our business.” Tim Irish, Partner at KHP Ventures added: "iFAST is ideally placed to tackle the .
